// AST – IMS - [DMinute_ROS]

Mark Sheptoff Financial Planning Trimmed Gilead Sciences (GILD) Stake By $607,110; Irobot (IRBT) Shorts Down By 17.49%

iRobot Corporation (NASDAQ:IRBT) Logo

Irobot Corporation (NASDAQ:IRBT) had a decrease of 17.49% in short interest. IRBT’s SI was 8.83 million shares in December as released by FINRA. Its down 17.49% from 10.70M shares previously. With 1.07 million avg volume, 8 days are for Irobot Corporation (NASDAQ:IRBT)’s short sellers to cover IRBT’s short positions. The SI to Irobot Corporation’s float is 33.01%. The stock decreased 4.89% or $4.6 during the last trading session, reaching $89.49. About 460,971 shares traded. iRobot Corporation (NASDAQ:IRBT) has risen 7.27% since December 6, 2017 and is uptrending. It has underperformed by 8.35% the S&P500. Some Historical IRBT News: 24/04/2018 – IROBOT 1Q REV. $217.1M, EST. $214.3M; 24/05/2018 – iRobot Short-Interest Ratio Rises 189% to 18 Days; 22/04/2018 – DJ iRobot Corporation, Inst Holders, 1Q 2018 (IRBT); 24/04/2018 – iRobot Short-Interest Ratio Rises 17% to 12 Days; 24/04/2018 – IROBOT CORP – REAFFIRMING 2018 FULL-YEAR REVENUE AND OPERATING INCOME EXPECTATIONS; 26/04/2018 – IROBOT CORP IRBT.O : JP MORGAN RAISES TARGET PRICE TO $62 FROM $61; 07/03/2018 Norges Bank Buys New 1.4% Position in iRobot; 25/04/2018 – It’s telling that $IRBT iRoomba is down even when they claim strong earnings; 24/04/2018 – iRobot 1Q EPS 71c; 24/04/2018 – iRobot 1Q Rev $217.1M

Mark Sheptoff Financial Planning Llc decreased Gilead Sciences Inc (GILD) stake by 97.59% reported in 2018Q2 SEC filing. Mark Sheptoff Financial Planning Llc sold 8,673 shares as Gilead Sciences Inc (GILD)’s stock rose 3.76%. The Mark Sheptoff Financial Planning Llc holds 214 shares with $15,000 value, down from 8,887 last quarter. Gilead Sciences Inc now has $89.34B valuation. The stock decreased 0.70% or $0.49 during the last trading session, reaching $69.06. About 2.86M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 12.47% since December 6, 2017 and is downtrending. It has underperformed by 28.09% the S&P500. Some Historical GILD News: 21/03/2018 – FOCUS-GlaxoSmithKline prescribes commercial reboot for pharma division; 01/05/2018 – GILEAD CEO JOHN MILLIGAN SPEAKS ON CALL; 09/05/2018 – Harish Manwani Joins Gilead Sciences’ Board of Directors; 16/04/2018 – Gilead’s Complera Rises After 1-Wk Fall, Triumeq Advances: HIV; 02/05/2018 – Gilead Slides as Street Looks for an End to Falling Sales; 09/05/2018 – Harish Manwani Joins Gilead Sciences’ Board of Directors; 06/03/2018 – Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys $GILD; 17/04/2018 – GE rides gene therapy wave with ready-made viral drug factories; 14/05/2018 – Gilead’s Epclusa Falls After 3-Wk Rise, Mavyret Advances: Hep-C; 26/03/2018 – Gilead’s Epclusa Rises After 1-Wk Fall, Harvoni Advances: Hep-C

Among 5 analysts covering Gilead Sciences (NASDAQ:GILD), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Gilead Sciences had 7 analyst reports since June 28, 2018 according to SRatingsIntel. Morgan Stanley maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Thursday, July 26. Morgan Stanley has “Equal-Weight” rating and $85 target. The rating was downgraded by Robert W. Baird on Thursday, July 26 to “Neutral”. Raymond James maintained the stock with “Strong Buy” rating in Friday, October 26 report. The firm earned “Overweight” rating on Friday, October 26 by Cantor Fitzgerald. The stock has “Neutral” rating by PiperJaffray on Friday, October 26.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 5. They expect $1.63 EPS, up 1.87% or $0.03 from last year’s $1.6 per share. GILD’s profit will be $2.11 billion for 10.59 P/E if the $1.63 EPS becomes a reality. After $1.70 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -4.12% negative EPS growth.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Nasdaq.com which released: “Gilead’s (GILD) Harvoni and Descovy Get Approval in China – Nasdaq” on December 05, 2018, also Nasdaq.com with their article: “Gilead (GILD) Announces Data on CAR T Therapy Candidate – Nasdaq” published on December 04, 2018, Nasdaq.com published: “Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know – Nasdaq” on December 03, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Nasdaq.com and their article: “Should Value Investors Consider Gilead (GILD) Stock Now? – Nasdaq” published on November 21, 2018 as well as Seekingalpha.com‘s news article titled: “CAR-T Cells In The Real World – Seeking Alpha” with publication date: November 23, 2018.

Investors sentiment decreased to 0.75 in Q2 2018. Its down 0.13, from 0.88 in 2018Q1. It dived, as 75 investors sold GILD shares while 532 reduced holdings. 89 funds opened positions while 366 raised stakes. 977.84 million shares or 0.14% more from 976.44 million shares in 2018Q1 were reported. Reliance Tru Communication Of Delaware invested in 5,518 shares or 0.06% of the stock. 87,469 are owned by Da Davidson &. Vermont-based Manchester Capital Mngmt Ltd Company has invested 0.21% in Gilead Sciences, Inc. (NASDAQ:GILD). The California-based Kcm Advsr Lc has invested 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Argi Inv Services Llc invested in 0.1% or 21,763 shares. Reilly Fin Advisors Ltd Company owns 716 shares or 0.01% of their US portfolio. Pension invested 0.37% in Gilead Sciences, Inc. (NASDAQ:GILD). Sns Ltd Liability Corporation invested 0.5% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Asset Management One Comm Ltd owns 2.14M shares for 0.33% of their portfolio. Neville Rodie & Shaw holds 0.31% or 41,053 shares. Fdx Advisors invested in 18,143 shares. First Allied Advisory Services has 0.41% invested in Gilead Sciences, Inc. (NASDAQ:GILD). St Germain D J Inc, Massachusetts-based fund reported 3,901 shares. Apg Asset Mgmt Nv accumulated 5.21 million shares or 0.58% of the stock. Banced holds 8,347 shares or 1.01% of its portfolio.

Since July 2, 2018, it had 0 buys, and 4 insider sales for $14.63 million activity. 50,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $3.48M were sold by MARTIN JOHN C.

Among 6 analysts covering iRobot (NASDAQ:IRBT), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. iRobot had 6 analyst reports since June 12, 2018 according to SRatingsIntel. The stock of iRobot Corporation (NASDAQ:IRBT) earned “Neutral” rating by PiperJaffray on Monday, October 8. As per Monday, November 5, the company rating was reinitiated by Canaccord Genuity. The firm earned “Buy” rating on Tuesday, June 12 by Piper Jaffray. As per Tuesday, September 4, the company rating was downgraded by Sidoti. Needham upgraded the shares of IRBT in report on Wednesday, October 24 to “Buy” rating. The stock of iRobot Corporation (NASDAQ:IRBT) earned “Market Perform” rating by Raymond James on Tuesday, July 10.

iRobot Corporation designs, builds, and sells robots for the consumer market worldwide. The company has market cap of $2.48 billion. It offers Roomba floor vacuuming robots; Braava family of automatic floor mopping robots; Mirra Pool Cleaning Robot to clean residential pools and removes debris as small as two microns from pool floors, walls, and stair; and Looj Gutter Cleaning Robot. It has a 38.11 P/E ratio.

Since June 12, 2018, it had 0 insider buys, and 16 insider sales for $28.17 million activity. 10,000 shares valued at $967,700 were sold by Weinstein Glen Daniel on Tuesday, August 21. 1,500 shares were sold by Stacy Michelle, worth $155,130 on Wednesday, August 22. Dean Alison sold $1.43M worth of stock. CAMPANELLO RUSSELL J sold $896,250 worth of stock or 11,950 shares. 743 shares were sold by ALI MOHAMAD, worth $82,547. 59,441 shares were sold by Cerda Christian, worth $6.39M. 13,334 shares were sold by Angle Colin M, worth $1.00M on Tuesday, June 12.

iRobot Corporation (NASDAQ:IRBT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.